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doi:10.1016/j.kjms.2011.06.020Abstract Overexpression of hypoxia-inducible factor-1 alpha is noted during the invasive and
metastatic process of transitional cell carcinoma. It will upregulate vascular endothelial
growth factor (VEGF) and drive proliferation, invasiveness, metastasis, and antiapoptotic
ability of cancer cells. We proposed that tyrosine kinase receptor inhibitor, sunitinib malated
(Sutent; Pfizer Inc., Taiwan), combined with chemotherapeutic drug may present synergistic
cytotoxic enhancement to transitional cell carcinoma cells with subsequent inhibition of their
cellular behaviors, including proliferation, invasiveness, and metastatic activity. The contents
of VEGF-A in mouse bladder tumor cells (MBT-2) and culture medium were detected by
quantification-polymerase chain reaction and Western blot individually. The inhibitory concen-
trations of various chemotherapeutic drugs, sunitinib, and their combination treatment in
MBT-2 were determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay. Microchamber transmembrane migration assay was applied in evaluation of the
inhibitory effects of different dosages of sunitinib and combination treatment on tumor cells.
The cell cycle and apoptosis were analyzed after combination therapy by flow cytometry. Vari-
ation in apoptotic pathway was elucidated by Western blot using specific antibodies with
cleaved PARP and caspase-3. Metastatic animal model mimicked by tail vein injection of
MBT-2 cells was used to evaluate the treatment efficiency in tumor weight and survival rate.
The mRNA and protein level of VEGF-A in MBT-2 cells increased by 70% at 48 hours interval
under hypoxia stress condition. In MTT assay, MBT-2 cells had shown the highest sensitivity
to epirubicin. Sunitinib combined with epirubicin had shown a synergistic cytotoxic effect to
MBT-2 cells. Sunitinib and its combination with epirubicin showed significant inhibition on
MBT-2 cells migration in microchambers. G2/M phase arrest and increased subG1 in cell cycle
was seen in the epirubicin and sunitinib combination treatment group. The activation ofUrology, Department of Surgery, Tri-Service General Hospital, 325 Section 2 Chengung Road, Taipei
net (D.-S. Yu).
vier Taiwan LLC. All rights reserved.
Targeted chemotherapy for bladder cancer 195apoptosis pathway was confirmed by increased cleaved caspase-3 and cleaved PARP in MBT-2
cells. In tail vein tumor inoculation C3H mice model, epirubicin alone and sunitinib combina-
tion therapy decreased tumor growth in lungs with marginal effect. Sunitinib and epirubicin
combination had shown a synergistic cytotoxic effect and inhibited cell migration ability in
MBT-2 cells. The combination can induce cell cycle arrest at G2/M phase and increase subG1
cells. Metastatic animal study also showed that sunitinib combined with epirubicin has
a marginal effect on inhibition of tumor growth of lungs. The tyrosine kinase receptor
inhibitor-targeted combined chemotherapy regimen may provide as a new treatment modality
for advanced bladder cancer in the future.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
In Taiwan, 1,985 new cases and 681 deaths of bladder
cancer were recorded for the year 2006 [1]. Approximately
30% of patients with superficial tumors will progress to
invasive transitional cell carcinoma (TCC), where radical
cystectomy is the standard therapy. Unfortunately, this
disease recurs in up to 50% of these patients despite surgery
and it is potentially lethal [2]. Currently, the available
treatment for advanced and metastatic bladder cancer is
systemic chemotherapy. Although randomized trials have
established an incremental benefit from the addition of
chemotherapy in this setting, many patients still have
disease relapse, and therefore it is necessary to investigate
more efficient treatment modalities for this disease entity.
The critical role of angiogenesis in tumor growth and
metastasis has prompted many efforts to develop anti-
angiogenic therapies, thus providing a rational drug target
for using angiogenic inhibitors in bladder cancer tumors [3].
Two split tyrosine kinase receptor (TKR) domainsdvascular
endothelial growth factor receptors (VEGFR) and platelet-
derived growth factor receptordplay prominent roles in
tumor angiogenesis [4]. Sunitinib malate is one of several
new antiangiogenic agents undergoing tests of efficacy in
the treatment of various types of cancer, including
gastrointestinal stromal tumors and renal cell carcinoma
[5]. Sunitinib malate can block the angiogenesis signaling
cascade (VEGFR, fetal liver kinase 1/kinase insert domain
receptor, and fms-like tyrosine kinase 1) and regulate
tumor growth and its angiogenesis. Therefore, inhibiting
these targets might be expected to result in broad anti-
tumor efficacy. This study attempts to verify the possible
synergistic effect of anticancer drug and sunitinib malate in
treating metastatic TCC and its underlying mechanisms.
Materials and methods
Cell line and medium
TCC cell line, mouse bladder tumor cells (MBT-2) (JCRB,
Tokyo, Japan) were cultivated in Roswell Park Memorial
Institute 1640 (RPMI-1640) medium supplemented with
10% fetal bovine serum (HyClone, DK), with 100 U/mL
penicillin, 50 mg/mL streptomycin, with nonessential
amino acid (HyClone, DK), and 0.01 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HyClone, DK). Confluent
cells were detached with 0.01 M EDTA.Reagents
Sunitinib malate (Sutent) was kindly provided by Pfizer Inc.,
Taiwan. About 25 mg of sunitinib was dissolved in 5 mL of
phosphate buffered saline (PBS) (pH 6.5) to make 5 mg/mL
stock. Epirubicin and gemcitabine were kindly provided by
TTY Biopharm, Taiwan, ROC. Paclitaxel was purchased from
Bristol-Myers Squibb in United States. Mitomycin C was
kindly provided by Kuai Kuai Co., Taiwan, ROC. CoCl2 was
purchased from SIGMA. CoCl2 (0.238 mg) was dissolved in
10 mL Q-H2O and filtered using 0.22 mM filter to make
100 mM stock solution.
Hypoxia and starvation challenge in MBT-2 cells
Around 6 105 MBT-2 cells were seeded in 10 cm petri dish
and allowed to attach overnight, and then the culture
medium was replaced with 100 mM CoCl2, serum-free
medium, or culture medium individually for 24 hours and
48 hours [6]. At the scheduled time point, culture media
and cells were collected and harvested for western blot and
quantitative polymerase chain reaction (Q-PCR) study.
RNA extraction and cDNA synthesis
Total RNA was extracted from cultured cells using
a commercially available RNA extraction kit (Trizol; Gibco,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. To avoid contamination by DNA during RNA
preparation, DNA was digested with RNase-free DNase I
(Gibco), as recommended by the supplier. cDNA was
synthesized by using Moloney murine leukemia virus high-
performance reverse transcriptase kit (Epicentre Biotech-
nologies, UK) according to the manufacturer’s instructions.
Quantitative polymerase chain reaction
Detection of VEGF-A mRNA was conducted by a three-step
procedure using the ABI 7500 instrument (ABI, USA). First,
mRNA was extracted from cell lysate. Second, cDNA was
synthesized with Moloney murine leukemia virus high-
performance reverse transcriptase kit using 1 mg of RNA and
0.2 mg oligo-dT serving as primers in a total volume of 20 mL
and diluted to 1/100 fold. Third, 4.5 mL of the cDNA was
amplified using 9 mL of the Smart Quant Green Master Mix
with dUTP & ROX (Protech, UK) and 0.9 mL of mixed primers
and 3.6 mL Q-H2O. During the Q-PCR reaction, a 125 base
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from the cDNA. The amplicon was detected by fluorescence
using a specific pair of VEGF-A primers: forward primer 50-
CTTGTTCAGAGCGGAGAAAGC-30 and reverse primer 50-
ACATCTGCAAGTACGTTCGTT-30. The fluorescence emitted
after hybridization to the template DNA was measured by
the ABI 7500 instrument. In a separate Q-PCR reaction,
mRNA encoding for hypoxanthine-guanine phosphoribosyl
transferase primers: forward primer 50-GTTAAGCAGTA-
CAGCCCCAAA-30 and reverse primer 50-AGGGCATATCCAA-
CAACAAACTT-30 was processed as a housekeeping gene. Its
product served as a control for RNA and relative quantifi-
cation. All PCR reactions were performed with hot start
activated with 15 minutes at 95C, 40 cycles of 15 seconds
at 95C, 30 seconds at 60C and 35 seconds at 72C, and 2
minutes at 72C.
Evaluation of the effect of chemotherapeutic drugs
and sunitinib on cancer cell viability
MBT-2 cells were exposed to chemotherapeutic drugs
combined with various concentrations of sunitinib for 48
hours. Cellular chemosensitivity was assayed using a modi-
fied 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide (MTT; Sigma) assay to determine cell viability
in vitro. In brief, MBT-2 cells (2000 per well) in 100 mL
culture medium were seeded into 96-well microplates and
incubated at 37C for 12 hours before drug exposure. The
plated cell numbers were calculated to keep control cells
growing in the exponential phase throughout the 48 hours
incubation period. For concurrent treatment, cells were
treated with both single chemotherapeutic drugs and
sunitinib (each in 100 mL of culture medium) simultaneously
and incubated for 48 hours. At the peak, 50 mL of MTT
(2 mg/mL in RPMI medium) was added to each well and
allowed to react for 3 hours. The blue formazan crystals
formed were pelleted to the well bottoms by centrifuga-
tion, separated from the supernatant, and dissolved in
100 mL of dimethyl sulfoxide. The optical density was
determined by absorbance spectrometry at 560 nm using an
ELISA reader (Multiskan ex, Thermo, USA). Three separate
experiments with triplicate runs in each were performed to
obtain mean cell viability. The drug concentrations inhib-
iting cell growth by 50% (IC50) were determined using the
computer software Calcusyn1 (Version 1.1.1, 1996; Biosoft
Inc., Cambridge, UK) [7].
Observed/expected ratio of combined cytotoxic
effects
The combined effects of chemotherapeutic drug and suni-
tinib were subjected to observed and expected ratio.
Control experiments replaced the active agent with drug-
free medium. By combining two agents at graded concen-
trations, numerous combined effects of growth inhibition
were obtained and analyzed using observed/expected (O/
E) ratio. Statistical function f(u)A,BZ f(u)Aþ f(u)B, where
f(u)AZ the fraction unaffected by drug A, f(u)BZ the
fraction unaffected by drug B, and f(u)A,BZ the fraction
unaffected by drugs A and B and formula: (A drug and B
drug combination survival rate)/[(A drug survival rate) (Bdrug survival rate)] were used for analysis. O/E ratio less
than 1, 1e2, and greater than 2 indicate synergism, addi-
tivism, and antagonism, respectively. The expected
(presumed to be additive or synergistic) and observed
survival rates of MBT-2 cells were obtained from three
independent drug-combined treatments. A statistically
significant difference was recognized by Student t test
when p value is less than 0.05 [8].
Transwell migration assay
Disposable 24-well cell culture inserts (Nunc, Thermo Fisher
Scientific, Demark) were used for migration studies. The
cell suspension was kept positioned on the hydrophilic filter
site located directly above the bottom wells. Each filter site
is 0.47 m2 in square and pores are 8 mm in diameter. Wells
(“lower chambers”) were filled with 100 mL of RPMI-1640
medium with sunitinib 3.47 mM, epirubicin 0.279 mM, and
0.279 mM epirubicin combined with sunitinib 3.47 mM. Pol-
ycarbonate filters were positioned on microplates and
secured in place with corner pins. MBT-2 cells in 100 mL
RPMI-1640 medium were placed directly onto the filter sites
(“upper chambers”) and incubated for 8 hours at 37C in 5%
CO2. Nonmigrating cells on the top of the filters were
removed by gently wiping the filters with cotton swabs.
Migrating cells on the bottom side were fixed for 10 minutes
in 50% methanol in PBS and stained with Giemsa for 3
minutes. Stained cells were then captured using a BX50
microscope (Olympus, Tokyo, Japan) and cells were quan-
tified using morphometry software (analysis FIVE, Soft
Imaging System). Differences between two data points
were determined by Student t test, where p value less than
0.05 was considered significant.
Propidium iodide stain for cell cycle analysis
Apoptotic body was evaluated by the propidium iodide
staining assay. MBT-2 cells were cultivated with medium
alone or medium containing 0.279 mM epirubicin combined
with sunitinib 3.47 mM, epirubicin 0.279 mM alone, and
sunitinib 3.47 mM alone. MBT-2 cells were harvested at the
end of treatment, rinsed twice with PBS, and stained with
propidium iodide (BD Biosciences, Franklin Lakes, NJ, USA).
Analysis was performed on the fluorescence-activated cell
sorting Calibur using CellQuest.
Western blotting for VEGF-A, cleaved caspase-3,
and cleaved PARP expression
Around 106 exponentially growing MBT-2 cells were treated
under hypoxia and starvation situation; medium alone;
medium containing 0.279 mM epirubicin combined with
sunitinib 3.47 mM, epirubicin alone, or sunitinib alone at
0 hour and 24 hours. Then they were pelleted by centrifu-
gation, washed with PBS twice, and resuspended in 100 mL
of radioimmunoprecipitation assay lysis buffer (Pierce,
USA) containing cocktail protease inhibitor (Thermo, USA).
Protein (50 mg) was electrophoresed for 2 hours in 12%
sodium dodecyl sulphate-polyacrylamide gels and then
transferred to polyvinylidene difluoride membranes (Milli-
pore) by electroblotter for 1 hour at 4C at 100 V.
Table 1 Inhibitory concentrations (ICs) of anticancer
drugs and sunitinib on mouse bladder tumor cells
Drugs IC25 (mM)
(mean SD)
IC50 (mM)
(mean SD)
IC75 (mM)
(mean SD)
Epirubicin 0.039 0.005 0.105 0.012 0.279 0.031
Mitomycin C 0.075 0.046 0.150 0.065 0.303 0.089
Gemcitabine 0.070 0.029 0.221 0.045 0.696 0.148
Paclitaxel 0.094 0.049 0.392 0.115 1.622 0.678
Sunitinib 1.630 0.324 3.472 0.712 7.396 1.562
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cleaved caspase-3 (1:1000; Cell signaling, USA), cleaved
PARP (1:1000; Cell signaling, USA), and a-tubulin (1:5000,
Epitomics, USA) were diluted in tris-buffered saline with
Tween 20 (TBST) containing 5% nonfat milk and membranes
were incubated for 1 hour with gentle agitation. The blots
were washed for three times with TBST and incubated with
goat anti-rabbit antibody conjugated to horseradish
peroxidase (1:1000 dilutions in TBST; Cell Signaling Biotech,
Boston, MA, USA) for 1 hour. After three successive washes
with TBST, Western blotting chemiluminescence reagent
(Pierce; Thermo Fisher Scientific Inc., Rockford, IL, USA)
was used for protein detection.
Metastatic animal model
Ten-week-old C3H/HeNCrNarl female mice were injected
through tail vein with 0.1 mL of MBT-2 cells (6 106 cells/
mL in 1:1 PBS/fetal bovine serum). Usually pulmonary
metastases will be established within 2 weeks after inocu-
lation. The daily sunitinib treatment group (10 mg/kg) was
started on Day 1e6, 8e13, and 15e20 intervals. The epi-
rubicin treatment group (0.4 mg/kg) was given at Day 1, 4,
8, 11, 15, and 18. The cotreatment group of sunitinib and
epirubicin complied with the same regimen.
Statistical analysis
The expression of mRNA, cytotoxicity in MTT, and tumor
volume were expressed with mean standard deviation.
The Mann-Whitney U test was used for statistical compar-
ison with differences considered significant at p value less
than 0.05. For cumulative survival rates, Kaplan-Meier
estimates were calculated for multiple comparisons
methods with differences considered statistically signifi-
cant at p value less than 0.05.Figure 1. The mRNA expression of VEGF-A of mouse bladder
tumor cells measured by quantitative polymerase chain reac-
tion showing significantly increased VEGF-A under hypoxia
challenge at 24 hours and 48 hours when compared with normal
control. HPRTZ hypoxanthine-guanine phosphoribosyl trans-
ferase; VEGF-AZ vascular endothelial growth factor-A.Results
VEGF-A mRNA expression in MBT-2 cells
The responsive expression of VEGF-A mRNA in MBT-2 cells
was enhanced during hypoxia stress condition with increase
of 2.0-fold (p< 0.05) and 1.6 (p< 0.01) at 24 hours and 48
hours individually (Fig. 1). Subsequently, MBT-2 cells had
markedly increased expression of VEGF-A protein when
compared with normoxia MBT-2 cells with a17.2-fold
(p< 0.001) at 24 hours. This result suggests that VEGF-A
expression in MBT-2 cells is in a conditioning responsive
pattern.
ICs of chemotherapeutic agent and sunitinib on
MBT-2 cells
MBT-2 cells in the exponential growth phases were treated
with different doses of chemotherapeutic agents for 48
hours. The results showed that these agents inhibited cell
growth in a dose-dependent manner. Among various anti-
cancer drugs, the IC50 was 0.105 mM, 0.150 mM, 0.221 mM,Table 2 Observed/expected (O/E) ratio of combined
cytotoxic effects of anticancer drugs and sunitinib on mouse
bladder tumor cells in different IC combinations
Combination Sunitinib
IC25
(O/E ratio)
p Sunitinib
IC50
(O/E ratio)
p
Epirubicin IC25 1.13 0.36 <0.05 1.34 0.40 <0.05
Epirubicin IC50 0.84 0.13 <0.001 0.91 0.26 <0.01
Epirubicin IC75 0.74 0.06 <0.05 0.81 0.12 <0.05
Gemcitabine IC25 1.47 0.05 <0.05 1.61 0.29
Gemcitabine IC50 1.43 0.25 <0.01 1.50 0.18 <0.01
Gemcitabine IC75 1.46 0.30 <0.01 1.59 0.37
Paclitaxel IC25 1.34 1.19 1.38 1.33
Paclitaxel IC50 1.30 0.53 1.46 0.71
Paclitaxel IC75 1.24 0.31 <0.05 1.34 0.44
Mitomycin C IC25 1.72 0.41 2.97 1.91
Mitomycin C IC50 1.92 0.38 3.03 1.54
Mitomycin C IC75 1.69 0.15 <0.05 3.20 1.31
Data are presented as mean standard deviation.
O/E ratio less than 1, 1e2, and more than 2 indicate synergism,
additivism, and antagonism, respectively.
Figure 2. Western blotting showing marked increased
17.2-fold expression of VEGF-A protein in culture medium of
mouse bladder tumor cells under hypoxia stress condition when
compared with normal control cells. VEGF-AZ vascular endo-
thelial growth factor-A.
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paclitaxel individually. The IC50 for sunitinib was 3.472 mM
to MBT-2 TCC cells (Table 1).
Observed and expected ratio of chemotherapeutic
agent and sunitinib on MBT-2 cells
The observed and expected ratio of combination cytotox-
icity was compared. The combined effects of both reagents
were analyzed at IC25, IC50, and IC75 concentrations of
chemotherapeutic agents combined with IC25 and IC50Figure 3. The transmembrane migration assay revealed that w
epirubicin, marked decreased cellular migration (arrows) was s
(A) control; (B) sunitinib treated; (C) epirubicin treated at 8 hoursconcentrations of sunitinib, which showed a prominent
synergistic growth inhibition of MBT-2 cells with O/E ratio
below 1 respectively (Table 2). In these combinational
groups, epirubicin cotreatment with sunitinib group had
a better effect in cell toxicity than other chemotherapeutic
agent cotreatment with sunitinib groups. The average O/E
ratio of sunitinib combination with epirubicin had the
synergistic effect in sunitinib IC25 and IC50 combined with
epirubicin IC75 (p< 0.05). On the contrary, in other
combination groups, such as sunitinib with gemcitabine,
paclitaxel, or mitomycin C, only additive effects were seen.
The response of VEGF-A in culture medium under
hypoxia stress challenge
Figure 2 shows a 17.2-fold increased expression of VEGF-A
protein in culture medium of MBT-2 cells under hypoxia
stress condition when compared with normal control cells
in Western blotting study.
MBT-2 cells migration change after treatment with
sunitinib, epirubicin, and their combination
MBT-2 cells were treated with 3.47 mM sunitinib and
0.279 mM epirubicin, epirubicin alone, sunitinib alone, or
culture medium in transmembrane chambers for 8 hours.
Figure 3 shows that the level of the transmigration of MBT-2
cells was reduced in 79.9%, 14.2%, and 79.2% individually
when compared with control.hen mouse bladder tumor cells were treated by sunitinib and
een when compared with cellular aggregations appeared in
; and (D) sunitinib and epirubicin treated.
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after sunitinib and epirubicin combination
treatment
As shown in Fig. 4, the percentage of apoptotic body (peak
of hypodiploid DNA before G1 phase) in MBT-2 cellsFigure 4. Flow cytometry assay of (A) apoptotic changes and (B
treatment by epirubicin alone, sunitinib alone, or their combinatiocotreated with sunitinib and epirubicin was 18.2% at 24
hours. The percentage of apoptosis in the cotreatment
group was higher than the sunitinib or epirubicin treatment
alone (18.2% vs. 3.8% or 10.2% individually). For cell cycle
changes, epirubicin alone and cotreatment group induced
cell cycle arrest at G2/M phase at 24 hours.) cell cycle redistribution of mouse bladder tumor cells after
n.
Figure 5. Effect of epirubicin combined with sunitinib
treatment on expression of (A) cleaved PARP and (B) cleaved
caspase-3 in mouse bladder tumor cells. Exponentially growing
mouse bladder tumor cells were treated by epirubicin,
sunitinib, or cotreated with epirubicin and sunitinib for 24
hours. Cell lysates were prepared and protein level of
cleaved PARP and caspase-3 were determined by immunoblot
analysis. (C) a-tubulin was used for normalization and verifi-
cation of protein loading. The results from three independent
experiments were quantified by densitometry. t test;
p< 0.001.
Figure 6. The wet lung weight in C3H mice measured in
38 days after treatment, including control group, sunitinib
treatment group, epirubicin treatment group, and their
combination.
200 C.-L. Wu et al.Cleaved caspase-3 and PARP induction in MBT-2
cells
As shown in Fig. 5, the expression of cleaved caspase-3
protein significantly increased to 51.8-fold and 95.9-fold
by epirubicin and epirubicin-sunitinib cotreatment at 24
hours individually (p< 0.001). Expression of cleaved PARP
protein also significantly increased to 40.0-fold and 34.5-
fold by epirubicin and epirubicin-sunitinib cotreatment at
24 hours individually (p< 0.001). These results suggested
that programmed cell death activated in MBT-2 cells after
treatment with epirubicin and epirubicin-sunitinib
cotreatment.
Wet lung weight and survival rate and in tumor-
bearing mice
En bloc wet weight of lung representing tumor burden was
measured when mice were sacrificed at Day 38. Control
mice received PBS treatment intraperitoneally. The suniti-
nib (10 mg/kg) treatment group was given injection 6 days
a week for 3 weeks. The epirubicin (0.4 mg/kg) treatment
group was given injection 3 days a week for 3 weeks. The
combination treatment group followed the same protocol in
equivalent dosages. The results showed that epirubicin
alone (0.51 0.11 g, 29.2%, pZ 0.211) and sunitinib
combined with epirubicin (0.46 0.11 g, 36.1%, pZ 0.121)
decreased tumor growth with marginal effect when
compared with the control group (0.72 0.12 g) (Figs. 6
and 7).
Survival rates of C3H mice after tail vein injection of
MBT-2 cells with lung metastases were recorded and
compared in each group for 3 weeks. In our study, epi-
rubicin treatment had the highest survival rate (Fig. 8).
Unfortunately, sunitinib and its combination with epirubicin
did not exhibit better or synergistic tumor suppression
effect compared with epirubicin treatment alone.Discussion
Intravesical immuno- and chemotherapy, surgery, and
systemic chemotherapy are all critical elements in
management of patients with bladder cancer. Despite
advances with these modalities, we continue to seek newer
treatment paradigms to improve patient outcomes. Tar-
geted therapy with novel agents directed at specific
molecular pathways is a promising avenue to achieve such
progress theoretically.
Although bladder cancer is fairly well genetically char-
acterized, clinical trials with molecularly targeted agents
have, in comparison to other solid tumors, such as lung,
breast and prostate, been few in number and largely
unsuccessful, with no new agents being registered in the
last 20 years. The great theoretical potential and the
multitude of possible targets and drug combinations
support further research into this emergent field of medical
treatment of urologic malignancies, especially in treatment
of advanced bladder carcinoma [9].
Experimental and clinical data, including the approval of
the multitargeted drugs sunitinib and sorafenib, indicate
that exciting results, including tumor regression, can be
expected from the combined targeting of different path-
ways in the tumor angiogenesis scenario, especially in
certain types of cancer. Sunitinib malate and sorafenib are
novel Food and Drug Administration-approved anti-
angiogenic agents, which have recently been demonstrated
to improve the progression-free survival in patients with
metastatic renal cell carcinoma [10].
The main mechanisms of these new drugs are defined as
preventing the tumor growth by the inhibition of angio-
genesis and the induction of apoptosis and necrosis via
acting on different types of VEGF, such as the several
agents, which have been demonstrated to be beneficial for
bladder carcinoma. Silay et al. [11] have suggested that
theoretically these two new agents may also increase the
progression-free survival of the patients with advanced
bladder carcinoma because of their antiangiogenic and
tumor cell apoptotic effects. Bradley et al. [12] have
Figure 7. Microscopical examination of tissue sections showed that much less MBT-2 pulmonary tumor nodules (arrows) devel-
oped in epirubicin and sunitinib with epirubicin combination treatment groups (C and D) (hematoxylin and eosin stain, 40).
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using sunitinib in advanced bladder cancer patients after
chemotherapy. Dreicer et al. [13] reported that using sor-
afenib as a single agent has minimal activity in patients
with advanced urothelial cancer in the second-line setting.
Sridhar et al. [14] had reported that sorafenib does
not show sufficient activity as a single agent in first-line
metastatic urothelial cancer. Gallagher et al. [15]Figure 8. The cumulative survival curve of C3H mice
bearing pulmonary mouse bladder tumor cells metastases after
treatment with sunitinib, epirubicin, or their combination.
Treatments lasted for 3 weeks and followed for another
3 weeks.reported sunitinib treatment had not reached the pre-
determined therapeutic threshold in metastatic urothelial
cancer patients but they did observe antitumor responses.
It has previously been shown that VEGF is abnormally
expressed in TCC and that it promotes cancer malignancy
[16]. In our study, the VEGF content was in parallel to
cellular differentiation of TCC cells (data not shown). The
specific hypothesis of this study is that sunitinib in
conjunction with anticancer drug will decrease tumor
volume of metastases and prolong tumor-carrying host
survival. Our rationale is that sunitinib may synergistically
enhance the cytotoxicity of anticancer drug to TCC cells
through its VEGF inhibition effect. Furthermore, as known
in our previous study, to counteract VEGF activity, sunitinib
also seems to be able to increase the apoptotic pathway of
tumor cells with increased intracellular bcl proteins (article
in press).
Hypoxia inducible factor has been reported to be closely
related to the invasiveness and progression of TCC [17].
Subsequently, the downstream regulator-VEGF will drive
proliferative, invasive, metastatic, and antiapoptotic
activity of tumor cells [18e21]. In our study, MBT-2 tumor
cells increased the expression of VEGF mRNA and protein
under CoCl2 hypoxia and serum-free stress condition, which
is similar to human TCC in previous reports [22,23].
The aim of this study was to identify most effective
combination of chemotherapeutic agents for metastatic
bladder cancer treatment. From in vitro MTT assay, epi-
rubicin has been selected as the first choice for combina-
tion trial with sunitinib to decrease the side effects and
202 C.-L. Wu et al.occurrence of drug resistance while increasing the cyto-
toxic efficacy. Epirubicin can inhibit synthesis of DNA and
RNA through inhibition of Type II topoisomerase and DNA
helicase, resulting in G2/M phase arrest of cell cycle
[24e27].
Sunitinib alone did not exhibit effect on cell cycle, but
when it was combined with epirubicin, the subG1 pop-
ulation increased, which indicates the activation of
apoptosis occurred after the combination treatment. From
Western blot analysis, marked increases in cleaved-PARP
and caspase-3 have been observed in MBT-2 cells after
epirubicin and sunitinib combination treatment. These
enzymes activities are closely related the cellular apoptosis
[28,29]. These results are similar to reports on other
cancers [30].
The possible underlying mechanisms of synergism of epi-
rubicin and sunitinib combination to TCC might include the
following: (1) sunitinib can inhibit membranous transporters
ATP-binding cassette sub-family B member 1 and ATP-
binding cassette sub-family G member 2 in tumor cells with
decreasing generation of multidrug resistance [31]; (2)
sunitinib can enhance the influx of epirubicin into tumor
cells [32]; and (3) sunitinib can increase the cleaved caspase-
2 activity in tumor cells with apoptosis development.
Other combination regimens of molecule-targeted
agents with anticancer drugs have been reported, such as
sunitinib combined with cisplatin in TCC treatment [9],
sunitinib combined with docetaxel in prostate cancer [33],
and sunitinib combined with gemcitabine in pancreatic
cancer [34]. Although the results were variable, all
observed increased cleaved caspase-3 activity after the
combination treatment. This indicates that caspase-3-
related apoptosis plays an important role in sunitinib for its
conduction of cytotoxicity to tumor cells when combined
with anticancer drugs.
The inhibitory ability of sunitinib and its combination
with epirubicin was also demonstrated by inhibition of
transmembrane migratory activity of MBT-2 cells in Fig. 3,
which indirectly hints its potential to prevent tumor
progression and metastasis.
In further animal study using a pulmonary metastatic
model of MBT-2 tumor cells, the therapeutic efficacy of
sunitinib and epirubicin was challenged with only
a marginal effect on tumor burden decrease and survival.
The possible underlying causes of inconsistency between
in vitro and in vivo aspects in our study might include the
following: (1) alternative maintenance pathway turn on in
tumor cells after the VEGF pathway was blocked by TKRi
treatment [35]; (2) relatively lower biological dosage of
sunitinib and epirubicin used in this study [36,37]; (3)
generation of drug resistance of tumor cells after repeated
treatment by sunitinib [38,39]; (4) frequency and regimen
of TKRi treatment; (5) angiogenesis dependency of pulmo-
nary tumors when compared with other organs; and (6)
larger tumor burden before treatment beginning [40].
Sunitinib combined with epirubicin could directly
contact to cancer cells in vitro. The microenvironment drug
concentration might be lower in vivo because of drug
delivery, metabolism, and systemic circulation with redis-
tribution. In our study, the sunitinib dosage might have
been too low to reach the level of significant therapeutic
effect on prolonging survival. In conclusion, limitedtreatment response of sunitinib and epirubicin has been
seen in bladder cancer in this study. The verification of
TKRi-targeted and anticancer drug (epirubicin) therapeutic
efficacy in metastatic bladder cancer still requires further
well-designed experiments.
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